{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:27:12Z","timestamp":1794335232129,"version":"4.9.0"},"reference-count":385,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872815"],"award-info":[{"award-number":["81872815"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872826"],"award-info":[{"award-number":["81872826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073801"],"award-info":[{"award-number":["82073801"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["18ZR1404100"],"award-info":[{"award-number":["18ZR1404100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.apsb.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T03:40:01Z","timestamp":1619667601000},"page":"2416-2448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":358,"title":["Oral delivery of proteins and peptides: Challenges, status quo and future perspectives"],"prefix":"10.1016","volume":"11","author":[{"given":"Quangang","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-2515","authenticated-orcid":false,"given":"Pijush Kumar","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-0814","authenticated-orcid":false,"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4833-1426","authenticated-orcid":false,"given":"Jianping","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2021.04.001_bib1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2174\/0929866521666140807114240","article-title":"Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles","volume":"21","author":"Patel","year":"2014","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.apsb.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/med.21579","article-title":"Bioactive peptides and proteins as alternative antiplatelet drugs","volume":"39","author":"Rengasamy","year":"2019","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1248\/bpb.b14-00508","article-title":"Enhanced oral bioavailability of morin administered in mixed micelle formulation with pluronic F127 and tween 80 in rats","volume":"38","author":"Choi","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.apsb.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2018.183","article-title":"Non-invasive delivery strategies for biologics","volume":"18","author":"Anselmo","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2021.04.001_bib5","series-title":"Peptide and protein delivery","author":"Van Der Walle","year":"2011"},{"key":"10.1016\/j.apsb.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2017.03.015","article-title":"Novel strategies in the oral delivery of antidiabetic peptide drugs\u2014insulin, GLP 1 and its analogs","volume":"115","author":"Ismail","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"14414","DOI":"10.1002\/anie.201807298","article-title":"Orally active peptides: is there a magic bullet?","volume":"57","author":"Rader","year":"2018","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.apsb.2021.04.001_bib8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide adme properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.apsb.2021.04.001_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2019.03.007","article-title":"Intracellular availability of poorly soluble drugs from lipid nanocapsules","volume":"139","author":"Bohley","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2013.02.030","article-title":"Approaches for enhancing oral bioavailability of peptides and proteins","volume":"447","author":"Renukuntla","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrd1067","article-title":"Challenges for the oral delivery of macromolecules","volume":"2","author":"Goldberg","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.drudis.2006.08.005","article-title":"Is the oral route possible for peptide and protein drug delivery?.","volume":"11","author":"Morishita","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib14","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/03639045.2019.1628770","article-title":"A review on parenteral delivery of peptides and proteins","volume":"45","author":"Jain","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/1061186X.2012.693499","article-title":"Strategies for non-invasive delivery of biologics","volume":"20","author":"Chung","year":"2012","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2021.04.001_bib16","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1517\/17425247.2014.945420","article-title":"Advances in oral macromolecular drug delivery","volume":"11","author":"Hwang","year":"2014","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.addr.2016.10.005","article-title":"Oral delivery of peptides: opportunities and issues for translation","volume":"106","author":"Brayden","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2016.01.010","article-title":"Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts","volume":"101","author":"Moroz","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib19","series-title":"Oral proteins and peptides market overview","author":"Shaikh","year":"2018"},{"key":"10.1016\/j.apsb.2021.04.001_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.addr.2018.07.001","article-title":"SEDDS: a game changing approach for the oral administration of hydrophilic macromolecular drugs","volume":"142","author":"Mahmood","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/17425247.2017.1395853","article-title":"Strategies and industrial perspectives to improve oral absorption of biological macromolecules","volume":"15","author":"Liu","year":"2018","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib23","article-title":"Oral delivery of biologics for precision medicine","volume":"32","author":"Duran-Lobato","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/17425247.2014.917077","article-title":"Oral peptide and protein delivery: intestinal obstacles and commercial prospects","volume":"11","author":"Smart","year":"2014","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1208\/s12249-019-1325-z","article-title":"Nanoparticles: oral delivery for protein and peptide drugs","volume":"20","author":"Cao","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/17425247.2018.1503250","article-title":"Silica nanoparticles on the oral delivery of insulin","volume":"15","author":"Tan","year":"2018","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib27","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/193229680900300323","article-title":"Oral insulin and buccal insulin: a critical reappraisal","volume":"3","author":"Heinemann","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib28","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/bmj.2.3286.1204","article-title":"Insulin in alcoholic solution by the mouth","volume":"2","author":"Harrison","year":"1923","journal-title":"Br Med J"},{"key":"10.1016\/j.apsb.2021.04.001_bib29","series-title":"Oral blood sugar lowering compositions","author":"Ferguson","year":"1965"},{"key":"10.1016\/j.apsb.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/jphp.12607","article-title":"Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities","volume":"68","author":"Wong","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jsps.2014.06.004","article-title":"A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives","volume":"24","author":"Muheem","year":"2016","journal-title":"Saudi Pharmaceut J"},{"key":"10.1016\/j.apsb.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"105280","DOI":"10.1016\/j.ejps.2020.105280","article-title":"Impact of gastrointestinal physiology on drug absorption in special populations\u2013\u2013an ungap review","volume":"147","author":"Stillhart","year":"2020","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib33","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1002\/jps.24274","article-title":"Investigation of pH and temperature profiles in the GI tract of fasted human subjects using the Intellicap\u00ae system","volume":"104","author":"Koziolek","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.29.8.1035","article-title":"Measurement of gastrointestinal pH profiles in normal ambulant human subjects","volume":"29","author":"Evans","year":"1988","journal-title":"Gut"},{"key":"10.1016\/j.apsb.2021.04.001_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2018.09.003","article-title":"Challenges and innovations of drug delivery in older age","volume":"135","author":"Khan","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib36","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1517\/17425255.2012.698261","article-title":"Ontogeny of oral drug absorption processes in children","volume":"8","author":"Mooij","year":"2012","journal-title":"Expet Opin Drug Metabol Toxicol"},{"key":"10.1016\/j.apsb.2021.04.001_bib37","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s40265-017-0832-z","article-title":"A review of food\u2013drug interactions on oral drug absorption","volume":"77","author":"Deng","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2021.04.001_bib38","first-page":"114","article-title":"Improved localizing method of radiopill in measurement of entire gastrointestinal ph profiles: colonic luminal pH in normal subjects and patients with Crohn's disease","volume":"92","author":"Sasaki","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.apsb.2021.04.001_bib39","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/BF01297074","article-title":"Very low intraluminal colonic pH in patients with active ulcerative colitis","volume":"38","author":"Fallingborg","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib40","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.3748\/wjg.v16.i43.5496","article-title":"Gastric juice acidity in upper gastrointestinal diseases","volume":"16","author":"Lu","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2021.04.001_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wei","year":"1999","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijbiomac.2018.07.143","article-title":"Enzyme structure and function protection from gastrointestinal degradation using enteric coatings","volume":"119","author":"Gracia","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2021.04.001_bib43","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1208\/s12248-016-9928-8","article-title":"The effects of pharmaceutical excipients on gastrointestinal tract metabolic enzymes and transporters\u2014an update","volume":"18","author":"Zhang","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.apsb.2021.04.001_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(97)00204-6","article-title":"The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins","volume":"52","author":"Bernkop-Schn\u00fcrch","year":"1998","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10620-006-9589-z","article-title":"Human pancreatic digestive enzymes","volume":"52","author":"Whitcomb","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.foodchem.2017.06.134","article-title":"Protein degradation and peptide release from milk proteins in human jejunum: comparison with in\u00a0vitro gastrointestinal simulation","volume":"239","author":"Sanch\u00f3n","year":"2018","journal-title":"Food Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib47","first-page":"61","article-title":"Enzymatic barriers for GI peptide and protein delivery","volume":"11","author":"Woodley","year":"1994","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.apsb.2021.04.001_bib48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1017\/S0954422414000225","article-title":"Are intact peptides absorbed from the healthy gut in the adult human?.","volume":"27","author":"Miner-Williams","year":"2015","journal-title":"Nutr Res Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijpharm.2015.05.006","article-title":"Liposomes containing cholesterol analogues of botanical origin as drug delivery systems to enhance the oral absorption of insulin","volume":"489","author":"Cui","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib50","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.apsb.2017.11.007","article-title":"Biomimetic thiamine- and niacin-decorated liposomes for enhanced oral delivery of insulin","volume":"8","author":"He","year":"2018","journal-title":"Acta Pharm Sinica B"},{"key":"10.1016\/j.apsb.2021.04.001_bib51","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.addr.2017.10.001","article-title":"Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties","volume":"124","author":"Wu","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib53","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.2042-7158.2011.01399.x","article-title":"Mucus thickness in the gastrointestinal tract of laboratory animals","volume":"64","author":"Varum","year":"2012","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles:the gastrointestinal mucus barriers","volume":"2012","author":"Ensign","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.09.023","article-title":"The biology of mucus: composition, synthesis and organization","volume":"124","author":"Bansil","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib56","doi-asserted-by":"crossref","first-page":"D1321","DOI":"10.2741\/Corfield","article-title":"Mucins in the gastrointestinal tract in health and disease","volume":"6","author":"Corfield","year":"2001","journal-title":"Front Biosci"},{"key":"10.1016\/j.apsb.2021.04.001_bib57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0006-291X(84)90213-4","article-title":"Effect of lipids and proteins on the viscosity of gastric mucus glycoprotein","volume":"121","author":"Murty","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2021.04.001_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cis.2017.12.005","article-title":"Gel-forming mucin interactome drives mucus viscoelasticity","volume":"252","author":"Demouveaux","year":"2018","journal-title":"Adv Colloid Interface Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib59","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.ph.57.030195.003025","article-title":"The hydrophobic barrier properties of gastrointestinal mucus","volume":"57","author":"Lichtenberger","year":"1995","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.apsb.2021.04.001_bib60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and recent progress in oral drug delivery systems for biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.04.001_bib61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bcpt.12342","article-title":"Mucus as a barrier to drug delivery\u2013understanding and mimicking the barrier properties","volume":"116","author":"Boegh","year":"2015","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2021.04.001_bib62","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2017.12.034","article-title":"Design and intestinal mucus penetration mechanism of core-shell nanocomplex","volume":"272","author":"Zhang","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib63","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2018.02.021","article-title":"Exploiting or overcoming the dome trap for enhanced oral immunization and drug delivery","volume":"275","author":"Qi","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib64","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/aja.1001410407","article-title":"Origin, differentiation and renewal of the four main epithelial cell types in the mouse small intestine: unitarian theory of the origin of the four epithelial cell types","volume":"141","author":"Cheng","year":"1974","journal-title":"Am J Anat"},{"key":"10.1016\/j.apsb.2021.04.001_bib65","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00109-017-1557-x","article-title":"Layered defense: how mucus and tight junctions seal the intestinal barrier","volume":"95","author":"Capaldo","year":"2017","journal-title":"J Mol Med"},{"key":"10.1016\/j.apsb.2021.04.001_bib66","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1080\/17474124.2017.1343143","article-title":"The intestinal barrier: a fundamental role in health and disease","volume":"11","author":"Vancamelbeke","year":"2017","journal-title":"Expet Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.04.001_bib67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrgastro.2016.169","article-title":"The intestinal epithelial barrier: a therapeutic target?.","volume":"14","author":"Odenwald","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2021.04.001_bib68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0016-5085(74)80102-2","article-title":"Epithelial cell specialization within human peyer's patches: an ultrastructural study of intestinal lymphoid follicles","volume":"66","author":"Owen","year":"1974","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2021.04.001_bib69","first-page":"823710","article-title":"Peyer's patches: the immune sensors of the intestine","volume":"2010","author":"Jung","year":"2010","journal-title":"Int J Inflamm"},{"key":"10.1016\/j.apsb.2021.04.001_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib71","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/0955-0674(93)90024-K","article-title":"The structure and regulation of tight junctions","volume":"5","author":"Anderson","year":"1993","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.apsb.2021.04.001_bib72","first-page":"G467","article-title":"Tight junctions and the molecular basis for regulation of paracellular permeability","volume":"269","author":"Anderson","year":"1995","journal-title":"Am J Physiol-gastr L"},{"key":"10.1016\/j.apsb.2021.04.001_bib73","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00018-012-1070-x","article-title":"Regulation of intestinal epithelial permeability by tight junctions","volume":"70","author":"Suzuki","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib74","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibtech.2009.07.009","article-title":"Therapeutic application of peptides and proteins: parenteral forever?","volume":"27","author":"Antosova","year":"2009","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.apsb.2021.04.001_bib75","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.ddtec.2011.11.006","article-title":"Overcoming poor permeability: translating permeation enhancers for oral peptide delivery","volume":"9","author":"Maher","year":"2012","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1126\/science.6259737","article-title":"Intestinal M cells: a pathway for entry of reovirus into the host","volume":"212","author":"Wolf","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.apsb.2021.04.001_bib77","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1021\/acs.molpharmaceut.5b00265","article-title":"Combinatorial approach of antigen delivery using M cell-homing peptide and mucoadhesive vehicle to enhance the efficacy of oral vaccine","volume":"12","author":"Singh","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib78","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ajpath.2011.10.019","article-title":"Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease","volume":"180","author":"M\u00e9nard","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2021.04.001_bib79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2018.08.032","article-title":"Oral peptide delivery: translational challenges due to physiological effects","volume":"287","author":"Tyagi","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib80","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00125-015-3538-3","article-title":"Upper gastrointestinal motility and symptoms in individuals with diabetes, prediabetes and normal glucose tolerance","volume":"58","author":"Boronikolos","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.apsb.2021.04.001_bib81","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1021\/acs.molpharmaceut.5b00602","article-title":"Analysis of intra- and inter- subject variability in oral drug absorption in human bioequivalence studies of 113 generic products","volume":"12","author":"Sugihara","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib82","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/1389200215666140926151642","article-title":"The modulating effects of endogenous substances on drug metabolising enzymes and implications for inter-individual variability and quantitative prediction","volume":"15","author":"Jamal Azam","year":"2014","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.apsb.2021.04.001_bib83","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.tox.2010.06.007","article-title":"PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals","volume":"278","author":"Bois","year":"2010","journal-title":"Toxicology"},{"key":"10.1016\/j.apsb.2021.04.001_bib84","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2018.07.011","article-title":"Parenteral protein formulations: an overview of approved products within the European Union","volume":"131","author":"Gervasi","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib85","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.copbio.2019.01.014","article-title":"Chemical and physical instabilities in manufacturing and storage of therapeutic proteins","volume":"60","author":"Krause","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.apsb.2021.04.001_bib86","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejpb.2019.03.021","article-title":"Antibody\u2013drug conjugates\u2014stability and formulation","volume":"139","author":"Duerr","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib87","doi-asserted-by":"crossref","first-page":"118505","DOI":"10.1016\/j.ijpharm.2019.118505","article-title":"Science and art of protein formulation development","volume":"568","author":"Wang","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib88","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jmb.2011.02.053","article-title":"Contribution of hydrophobic interactions to protein stability","volume":"408","author":"Pace","year":"2011","journal-title":"J Mol Biol"},{"key":"10.1016\/j.apsb.2021.04.001_bib89","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.febslet.2014.05.006","article-title":"Forces stabilizing proteins","volume":"588","author":"Nick Pace","year":"2014","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2021.04.001_bib90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ejps.2016.11.016","article-title":"Diversity selection, screening and quantitative structure\u2013activity relationships of osmolyte-like additive effects on the thermal stability of a monoclonal antibody","volume":"97","author":"Oyetayo","year":"2017","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib91","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijpharm.2018.09.057","article-title":"Unexplored benefits of controlled ice nucleation: lyophilization of a highly concentrated monoclonal antibody solution","volume":"552","author":"Singh","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib92","doi-asserted-by":"crossref","first-page":"10897","DOI":"10.1021\/acs.analchem.8b02402","article-title":"Non-enzymatic and site-specific glycan shedding: a novel protein degradation pathway observed in a stabilized form of RSV prefusion F protein","volume":"90","author":"Qian","year":"2018","journal-title":"Anal Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib93","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.xphs.2017.12.015","article-title":"Predicting protein\u2012protein interactions of concentrated antibody solutions using dilute solution data and coarse-grained molecular models","volume":"107","author":"Calero-Rubio","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib94","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1016\/j.xphs.2017.07.018","article-title":"Overcoming challenges with intravenous administration of an investigational protein therapeutic","volume":"106","author":"Shi","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.06.011","article-title":"Advances in liquid formulations of parenteral therapeutic proteins","volume":"37","author":"Falconer","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.apsb.2021.04.001_bib96","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.biologicals.2011.04.003","article-title":"Different effects of L-arginine on the heat-induced unfolding and aggregation of proteins","volume":"39","author":"Cirkovas","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.apsb.2021.04.001_bib97","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/1061186X.2019.1669043","article-title":"Protein drug delivery: current dosage form profile and formulation strategies","volume":"28","author":"Geraldes","year":"2020","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2021.04.001_bib98","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11095-016-2058-2","article-title":"Photo-oxidation of IGG1 and model peptides: detection and analysis of triply oxidized his and trp side chain cleavage products","volume":"34","author":"Bane","year":"2017","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib99","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.addr.2011.07.006","article-title":"Protein\u2013excipient interactions: mechanisms and biophysical characterization applied to protein formulation development","volume":"63","author":"Kamerzell","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib100","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jps.24655","article-title":"Addition of amino acids to further stabilize lyophilized sucrose-based protein formulations: I. screening of 15 amino acids in two model proteins","volume":"105","author":"Forney-Stevens","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib101","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10837450701481157","article-title":"Protein stability during freezing: separation of stresses and mechanisms of protein stabilization","volume":"12","author":"Bhatnagar","year":"2007","journal-title":"Pharmaceut Dev Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib102","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejpb.2018.04.005","article-title":"Surfactants as stabilizers for biopharmaceuticals: an insight into the molecular mechanisms for inhibition of protein aggregation","volume":"128","author":"Arsiccio","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib103","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/ijms20051252","article-title":"Protein interaction with charged macromolecules: from model polymers to unfolded proteins and post-translational modifications","volume":"20","author":"Semenyuk","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib104","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.carbpol.2018.03.034","article-title":"Protein adsorption onto polysaccharides: comparison of chitosan and chitin polymers","volume":"191","author":"Yahyaei","year":"2018","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2021.04.001_bib105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.foodchem.2017.06.115","article-title":"Monitoring protein hydrolysis by pepsin using pH-stat: in\u00a0vitro gastric digestions in static and dynamic ph conditions","volume":"239","author":"Mat","year":"2018","journal-title":"Food Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib106","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ijbiomac.2018.02.016","article-title":"Eudragit\u00ae L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery","volume":"113","author":"Xu","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2021.04.001_bib107","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1015893832222","article-title":"Degradation of insulin by trypsin and alpha-chymotrypsin","volume":"8","author":"Schilling","year":"1991","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib108","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejpb.2013.12.017","article-title":"The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition","volume":"86","author":"Welling","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib109","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1023\/A:1014849630520","article-title":"Impact of regional intestinal ph modulation on absorption of peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs","volume":"16","author":"Lee","year":"1999","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib110","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/jbmr.1602","article-title":"A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (oracal) trial","volume":"27","author":"Binkley","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib111","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","article-title":"A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules","volume":"32","author":"Choonara","year":"2014","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.apsb.2021.04.001_bib112","first-page":"1155","article-title":"Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in\u00a0vitro characterization, and improved protection against enzymatic degradation","volume":"6","author":"Niu","year":"2011","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2021.04.001_bib113","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1211\/146080800128735935","article-title":"Oral delivery of proteins: effect of chicken and duck ovomucoid on the stability of insulin in the presence of \u03b1-chymotrypsin and trypsin","volume":"6","author":"Agrwal","year":"2000","journal-title":"Pharm Pharmcol Commun"},{"key":"10.1016\/j.apsb.2021.04.001_bib114","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1932296817691303","article-title":"Oral insulin delivery in a physiologic context","volume":"11","author":"Arbit","year":"2017","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib115","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/jps.22560","article-title":"Oral delivery system for two-pulse colonic release of protein drugs and protease inhibitor\/absorption enhancer compounds","volume":"100","author":"Del Curto","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib116","doi-asserted-by":"crossref","first-page":"105019","DOI":"10.1016\/j.ejps.2019.105019","article-title":"Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability","volume":"138","author":"Maderuelo","year":"2019","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib117","first-page":"152","article-title":"Eudragit a versatile polymer: a review","volume":"1","author":"Nikam","year":"2011","journal-title":"Pharmacologyonline"},{"key":"10.1016\/j.apsb.2021.04.001_bib118","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/187221109788452221","article-title":"Oral protein delivery: a patent review of academic and industrial approaches","volume":"3","author":"Werle","year":"2009","journal-title":"Recent Pat Drug Deliv Formulation"},{"key":"10.1016\/j.apsb.2021.04.001_bib119","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijpharm.2014.10.039","article-title":"Self-nanoemulsifying drug delivery systems for oral insulin delivery: in\u00a0vitro and in\u00a0vivo evaluations of enteric coating and drug loading","volume":"477","author":"Li","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib120","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1016\/j.biomaterials.2010.01.042","article-title":"Enteric-coated capsules filled with freeze-dried chitosan\/poly(\u03b3-glutamic acid) nanoparticles for oral insulin delivery","volume":"31","author":"Sonaje","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib121","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejps.2010.12.007","article-title":"Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery","volume":"42","author":"Makhlof","year":"2011","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib122","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i1.30","article-title":"Oral colon-specific drug delivery of protein and peptide drugs","volume":"24","author":"Sinha","year":"2007","journal-title":"Crit Rev Ther Drug"},{"key":"10.1016\/j.apsb.2021.04.001_bib123","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i2.20","article-title":"Therapeutic opportunities in colon-specific drug-delivery systems","volume":"24","author":"Patel","year":"2007","journal-title":"Crit Rev Ther Drug"},{"key":"10.1016\/j.apsb.2021.04.001_bib124","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1208\/s12249-016-0594-z","article-title":"Eudragit S100-coated chitosan nanoparticles co-loading TAT for enhanced oral colon absorption of insulin","volume":"18","author":"Chen","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2021.04.001_bib125","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.carbpol.2017.04.090","article-title":"Starch-based nanocapsules fabricated through layer-by-layer assembly for oral delivery of protein to lower gastrointestinal tract","volume":"171","author":"Zhang","year":"2017","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2021.04.001_bib126","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejpb.2017.11.012","article-title":"Retrograded starch\/pectin coated gellan gum-microparticles for oral administration of insulin: a technological platform for protection against enzymatic degradation and improvement of intestinal permeability","volume":"123","author":"Meneguin","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib127","first-page":"11","article-title":"Colon targeting drug delivery system: a review on recent approaches","volume":"2","author":"Kumar","year":"2011","journal-title":"Int J Pharma Bio Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.msec.2017.10.003","article-title":"A review of recent progress in drug and protein encapsulation: approaches, applications and challenges","volume":"83","author":"Ye","year":"2018","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.apsb.2021.04.001_bib129","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1016\/j.vaccine.2018.05.087","article-title":"Chitosan\/alginate microparticles for the oral delivery of fowl typhoid vaccine: innate and acquired immunity","volume":"36","author":"Onuigbo","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2021.04.001_bib130","doi-asserted-by":"crossref","first-page":"42492","DOI":"10.1021\/acsami.7b11821","article-title":"Influence of particle geometry on gastrointestinal transit and absorption following oral administration","volume":"9","author":"Li","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2021.04.001_bib131","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2016.07.051","article-title":"Role of nanoparticle size, shape and surface chemistry in oral drug delivery","volume":"238","author":"Banerjee","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib132","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein pegylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib133","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.addr.2016.02.004","article-title":"Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials","volume":"106","author":"Aguirre","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib134","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1021\/bc800258v","article-title":"Development of poly(ethylene glycol) conjugated lactoferrin for oral administration","volume":"19","author":"Nojima","year":"2008","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2008.12.014","article-title":"Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly (ethylene glycol)methyl ether methacrylate) yields a bioactive stable conjugate","volume":"135","author":"Ryan","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib136","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.2174\/138161210793292555","article-title":"Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization","volume":"16","author":"Gentilucci","year":"2010","journal-title":"Curr Pharmaceut Des"},{"key":"10.1016\/j.apsb.2021.04.001_bib137","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/bip.22767","article-title":"Approaches to the stabilization of bioactive epitopes by grafting and peptide cyclization","volume":"106","author":"Conibear","year":"2016","journal-title":"Pept Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib138","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bmc.2017.11.017","article-title":"From nature to creation: going around in circles, the art of peptide cyclization","volume":"26","author":"Zhang","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib139","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1507\/endocrj1954.32.547","article-title":"Resistance of 1-deamino[8-d-argininei]-vasopressin to in\u00a0vitro degradation as compared with arginine vasopressin","volume":"32","author":"Matsui","year":"1985","journal-title":"Endocrinol Jpn"},{"key":"10.1016\/j.apsb.2021.04.001_bib140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nchem.1062","article-title":"Contemporary strategies for peptide macrocyclization","volume":"3","author":"White","year":"2011","journal-title":"Nat Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib141","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1034\/j.1399-3011.1999.00052.x","article-title":"Solution stability of linear vs. cyclic RGD peptides","volume":"53","author":"Bogdanowich-Knipp","year":"1999","journal-title":"J Pept Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib142","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1021\/acs.chemrev.6b00838","article-title":"Orally absorbed cyclic peptides","volume":"117","author":"Nielsen","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib143","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2008.11.002","article-title":"Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues","volume":"61","author":"Lai","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib144","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/adma.201201800","article-title":"Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery","volume":"24","author":"Ensign","year":"2012","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib145","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/adhm.201600599","article-title":"Mucus-penetrating nanosuspensions for enhanced delivery of poorly soluble drugs to mucosal surfaces","volume":"5","author":"Yu","year":"2016","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib146","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2217\/nnm.10.123","article-title":"Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine","volume":"6","author":"Suk","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib147","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/014860719902300119","article-title":"Role of intestinal mucus on the uptake of latex beads by peyer's patches and on their transport to mesenteric lymph nodes in rats","volume":"23","author":"Khan","year":"1999","journal-title":"Jpen-parenter Enter"},{"key":"10.1016\/j.apsb.2021.04.001_bib148","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib149","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","article-title":"Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse","volume":"197","author":"Maisel","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.addr.2017.08.010","article-title":"Pegylation for enhancing nanoparticle diffusion in mucus","volume":"124","author":"Huckaby","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib151","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.nano.2016.04.006","article-title":"Mucus-penetrating nanoparticles made with \u201cmucoadhesive\u201d poly(vinyl alcohol)","volume":"12","author":"Popov","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib152","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1021\/acsnano.5b00028","article-title":"Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin","volume":"9","author":"Shan","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2021.04.001_bib153","doi-asserted-by":"crossref","first-page":"1801123","DOI":"10.1002\/adhm.201801123","article-title":"Protein corona liposomes achieve efficient oral insulin delivery by overcoming mucus and epithelial barriers","volume":"8","author":"Wang","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib154","doi-asserted-by":"crossref","first-page":"9916","DOI":"10.1021\/acsami.7b16524","article-title":"Biomimetic virus like and charge reversible nanoparticles to sequentially overcome mucus and epithelial barriers for oral insulin delivery","volume":"10","author":"Wu","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2021.04.001_bib155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jconrel.2019.06.015","article-title":"Impacts of particle shapes on the oral delivery of drug nanocrystals: mucus permeation, transepithelial transport and bioavailability","volume":"307","author":"Guo","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib156","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1021\/acs.nanolett.6b03515","article-title":"Rotation-facilitated rapid transport of nanorods in mucosal tissues","volume":"16","author":"Yu","year":"2016","journal-title":"Nano Lett"},{"key":"10.1016\/j.apsb.2021.04.001_bib157","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejpb.2015.01.022","article-title":"Nano-carrier systems: strategies to overcome the mucus gel barrier","volume":"96","author":"D\u00fcnnhaupt","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib158","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejpb.2016.09.013","article-title":"Development, in\u00a0vitro and in\u00a0vivo evaluation of a self-emulsifying drug delivery system (sedds) for oral enoxaparin administration","volume":"109","author":"Zupan\u010di\u010d","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib159","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0016-5085(19)35011-5","article-title":"Secretion and function of intestinal mucus","volume":"43","author":"Florey","year":"1962","journal-title":"Gastroenterology"},{"key":"10.1016\/j.apsb.2021.04.001_bib160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(97)00054-0","article-title":"Bioadhesive microspheres: III. an in\u00a0vivo transit and bioavailability study of drug-loaded alginate and poly(fumaric-co-sebacic anhydride) microspheres","volume":"48","author":"Chickering","year":"1997","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib161","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0168-3659(90)90133-E","article-title":"Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches","volume":"11","author":"Eldridge","year":"1990","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib162","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijpharm.2007.07.035","article-title":"In\u00a0vitro and in\u00a0vivo study of n-trimethyl chitosan nanoparticles for oral protein delivery","volume":"349","author":"Chen","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib163","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.addr.2005.07.002","article-title":"Thiomers: a new generation of mucoadhesive polymers","volume":"57","author":"Bernkop-Schn\u00fcrch","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib164","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0378-5173(03)00271-0","article-title":"Thiolated polymers\u2014thiomers: synthesis and in\u00a0vitro evaluation of chitosan\u20132-iminothiolane conjugates","volume":"260","author":"Bernkop-Schn\u00fcrch","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib165","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1016\/j.biomaterials.2009.06.055","article-title":"Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery","volume":"30","author":"Yin","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib166","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0168-3659(99)00228-X","article-title":"Lectin-mediated drug delivery: the second generation of bioadhesives","volume":"65","author":"Lehr","year":"2000","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib167","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.carbpol.2011.04.070","article-title":"Lectin-functionalized carboxymethylated kappa-carrageenan microparticles for oral insulin delivery","volume":"86","author":"Leong","year":"2011","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2021.04.001_bib168","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2006.07.026","article-title":"Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin","volume":"327","author":"Zhang","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib169","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.drudis.2011.05.013","article-title":"Patches for improving gastrointestinal absorption: an overview","volume":"16","author":"Teutonico","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib170","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coph.2017.08.005","article-title":"Intestinal patch systems for oral drug delivery","volume":"36","author":"Banerjee","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib171","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1015118923204","article-title":"Intestinal patches for oral drug delivery","volume":"19","author":"Shen","year":"2002","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib172","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jconrel.2013.09.004","article-title":"Mucoadhesive intestinal devices for oral delivery of salmon calcitonin","volume":"172","author":"Gupta","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib173","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2004.04.013","article-title":"Oral delivery of macromolecules using intestinal patches: applications for insulin delivery","volume":"98","author":"Whitehead","year":"2004","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib174","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/1061186X.2017.1300664","article-title":"Intestinal micropatches for oral insulin delivery","volume":"25","author":"Banerjee","year":"2017","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2021.04.001_bib175","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.actbio.2011.09.023","article-title":"Intestinal patches with an immobilized solid-in-oil formulation for oral protein delivery","volume":"8","author":"Toorisaka","year":"2012","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2021.04.001_bib176","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s10439-016-1558-x","article-title":"Delivery of exenatide and insulin using mucoadhesive intestinal devices","volume":"44","author":"Gupta","year":"2016","journal-title":"Ann Biomed Eng"},{"key":"10.1016\/j.apsb.2021.04.001_bib177","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1517\/14712598.4.6.881","article-title":"Hydrogels for oral delivery of therapeutic proteins","volume":"4","author":"Peppas","year":"2004","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.apsb.2021.04.001_bib178","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2008.11.014","article-title":"Complexation hydrogels for intestinal delivery of interferon \u03b2 and calcitonin","volume":"134","author":"Kamei","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib179","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jconrel.2003.12.022","article-title":"Oral insulin delivery using p(MAA-g-EG) hydrogels: effects of network morphology on insulin delivery characteristics","volume":"95","author":"Nakamura","year":"2004","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5173(02)00361-7","article-title":"Intestinal absorption of human insulin in pigs using delivery systems based on superporous hydrogel polymers","volume":"247","author":"Dorkoosh","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib181","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.biomaterials.2006.11.008","article-title":"Superporous hydrogels containing poly(acrylic acid-co-acrylamide)\/O-carboxymethyl chitosan interpenetrating polymer networks","volume":"28","author":"Yin","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib182","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/j.biomaterials.2010.01.045","article-title":"Polymer integrity related absorption mechanism of superporous hydrogel containing interpenetrating polymer networks for oral delivery of insulin","volume":"31","author":"Yin","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib183","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0169-409X(97)00045-8","article-title":"Improvement of oral peptide bioavailability: peptidomimetics and prodrug strategies","volume":"27","author":"Pauletti","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib184","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0168-3659(99)00042-5","article-title":"Optimizing oral absorption of peptides using prodrug strategies","volume":"62","author":"Borchardt","year":"1999","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.2042-7158.1992.tb05463.x","article-title":"Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats","volume":"44","author":"Hashizume","year":"1992","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib186","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1359-6446(03)02692-8","article-title":"Oral peptide and protein delivery: unfulfilled promises?","volume":"8","author":"Shen","year":"2003","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib187","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0014-5793(95)00910-2","article-title":"Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides","volume":"371","author":"Ekrami","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2021.04.001_bib188","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0168-3659(03)00008-7","article-title":"Reversible lipidization for the\u00a0oral delivery of salmon calcitonin","volume":"88","author":"Wang","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib189","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijpharm.2012.05.033","article-title":"Targeted lipid based drug conjugates: a novel strategy for drug delivery","volume":"434","author":"Vadlapudi","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib190","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/190263a0","article-title":"Gastro-intestinal absorption of heparin and synthetic heparinoids","volume":"190","author":"Windsor","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2021.04.001_bib191","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.biomaterials.2011.12.038","article-title":"Protease\u00a0inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery","volume":"33","author":"Su","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib192","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2013.11.028","article-title":"Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study","volume":"460","author":"Niu","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib193","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijpharm.2012.10.025","article-title":"Integrity and stability of oral liposomes containing bile salts studied in simulated and ex\u00a0vivo gastrointestinal media","volume":"441","author":"Hu","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib194","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2012.02.009","article-title":"Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose","volume":"81","author":"Niu","year":"2012","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib195","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2174\/1567201053586001","article-title":"Oral delivery of insulin with the eligen\u00ae technology: mechanistic studies","volume":"2","author":"Malkov","year":"2005","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib196","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1023\/A:1012160703533","article-title":"Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate: pharmacological considerations","volume":"14","author":"Rivera","year":"1997","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib197","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/pharmaceutics11020078","article-title":"Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium (SNAC) and sodium caprate (C10)","volume":"11","author":"Twarog","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.04.001_bib198","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1365-2125.2012.04278.x","article-title":"Gut hormones: the future of obesity treatment?.","volume":"74","author":"McGavigan","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib199","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/dia.2019.0185","article-title":"Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist","volume":"22","author":"Bucheit","year":"2020","journal-title":"Diabetes Technol Therapeut"},{"key":"10.1016\/j.apsb.2021.04.001_bib200","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1023\/A:1012192115828","article-title":"Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl) amino] caprylate in rat in situ intestinal instillations and in Caco-2 monolayers","volume":"14","author":"Brayden","year":"1997","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib201","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1477-9560-4-6","article-title":"Oral heparin: status review","volume":"4","author":"Arbit","year":"2006","journal-title":"Thromb J"},{"key":"10.1016\/j.apsb.2021.04.001_bib202","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.addr.2003.10.045","article-title":"Intestinal epithelial tight junctions as targets for enteric bacteria-derived toxins","volume":"56","author":"Fasano","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib203","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1172\/JCI118114","article-title":"Zonula occludens toxin modulates tight junctions through protein kinase c-dependent actin reorganization, in\u00a0vitro","volume":"96","author":"Fasano","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.apsb.2021.04.001_bib204","doi-asserted-by":"crossref","first-page":"19160","DOI":"10.1074\/jbc.M009674200","article-title":"Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain","volume":"276","author":"Di Pierro","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib205","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijpharm.2008.08.047","article-title":"Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer","volume":"365","author":"Gopalakrishnan","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib206","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.12147","article-title":"Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study","volume":"37","author":"Kelly","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.apsb.2021.04.001_bib207","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1124\/mol.64.6.1530","article-title":"A new principle for tight junction modulation based on occludin peptides","volume":"64","author":"Tavelin","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib208","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1083\/jcb.147.1.195","article-title":"Clostridium perfringens enterotoxin fragment removes specific claudins from tight junction strands: evidence for direct involvement of claudins in tight junction barrier","volume":"147","author":"Sonoda","year":"1999","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2021.04.001_bib209","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.33549\/physiolres.933975","article-title":"Cell-penetrating peptides: a useful tool for the delivery of various cargoes into cells","volume":"67","author":"B\u00f6hmov\u00e1","year":"2018","journal-title":"Physiol Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib210","doi-asserted-by":"crossref","first-page":"10444","DOI":"10.1016\/S0021-9258(17)34080-2","article-title":"The third helix of the antennapedia homeodomain translocates through biological membranes","volume":"269","author":"Derossi","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2021.04.001_bib211","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.addr.2016.04.031","article-title":"Using peptides to increase transport across the intestinal barrier","volume":"106","author":"S\u00e1nchez-Navarro","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib212","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbamem.2018.05.015","article-title":"Impact of cell-penetrating peptides (CPPs) melittin and HIV-1 TAT on the enterocyte brush border using a mucosal explant system","volume":"1860","author":"Danielsen","year":"2018","journal-title":"Biochim Biophys Acta-Biomembranes"},{"key":"10.1016\/j.apsb.2021.04.001_bib213","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijpharm.2018.05.055","article-title":"The use of low molecular weight protamine to enhance oral absorption of exenatide","volume":"547","author":"Zhang","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib214","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1248\/bpb.b17-00798","article-title":"Exploration of the key factors for optimizing the in\u00a0vivo oral delivery of insulin by using a noncovalent strategy with cell-penetrating peptides","volume":"41","author":"Kamei","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.apsb.2021.04.001_bib215","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.drudis.2014.03.001","article-title":"Ligand-mediated active targeting for enhanced oral absorption","volume":"19","author":"Zhang","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib216","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2217\/nnm.12.31","article-title":"Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin","volume":"7","author":"Jain","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib217","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nano.2013.07.011","article-title":"Biotinylated liposomes as potential carriers for the oral delivery of insulin","volume":"10","author":"Zhang","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib218","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2007.05.019","article-title":"Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles","volume":"122","author":"Chalasani","year":"2007","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib219","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2015.12.017","article-title":"Vitamin B12 functionalized layer by layer calcium phosphate nanoparticles: a mucoadhesive and ph responsive carrier for improved oral delivery of insulin","volume":"31","author":"Verma","year":"2016","journal-title":"Acta Biomater"},{"key":"10.1016\/j.apsb.2021.04.001_bib220","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1016\/j.biomaterials.2013.01.079","article-title":"Galactosylated trimethyl chitosan\u2013cysteine nanoparticles loaded with MAP4k4 siRNA for targeting activated macrophages","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib221","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/10717544.2018.1551441","article-title":"Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability","volume":"26","author":"Byeon","year":"2019","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib222","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0304-4165(02)00319-7","article-title":"The mannose receptor family","volume":"1572","author":"East","year":"2002","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.apsb.2021.04.001_bib223","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.matlet.2016.10.117","article-title":"Oral delivery of insulin using CaCO3-based composite nanocarriers with hyaluronic acid coatings","volume":"188","author":"Liu","year":"2017","journal-title":"Mater Lett"},{"key":"10.1016\/j.apsb.2021.04.001_bib224","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jconrel.2009.09.007","article-title":"Human growth hormone\u2013transferrin fusion protein for oral delivery in hypophysectomized rats","volume":"141","author":"Amet","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib225","doi-asserted-by":"crossref","first-page":"213ra167","DOI":"10.1126\/scitranslmed.3007049","article-title":"Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery","volume":"5","author":"Pridgen","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2021.04.001_bib226","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2005.01.018","article-title":"Investigation of lectin-modified insulin liposomes as carriers for oral administration","volume":"294","author":"Zhang","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib227","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.3109\/10717544.2015.1058433","article-title":"A novel ligand conjugated nanoparticles for oral insulin delivery","volume":"23","author":"Liu","year":"2016","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib228","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.biomaterials.2011.10.075","article-title":"Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport","volume":"33","author":"Jin","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib229","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.4155\/tde.11.129","article-title":"Intestinal receptor targeting for peptide delivery: an expert's personal perspective on reasons for failure and new opportunities","volume":"2","author":"Russell-Jones","year":"2011","journal-title":"Ther Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib230","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/117739280700200003","article-title":"Targeting receptors, transporters and site of absorption to improve oral drug delivery","volume":"2","author":"Hamman","year":"2007","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.apsb.2021.04.001_bib231","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.2217\/nnm-2017-0372","article-title":"Targeted folate-conjugated pluronic P85\/poly(lactide-co-glycolide) polymersome for the oral delivery of insulin","volume":"13","author":"Xie","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib232","doi-asserted-by":"crossref","DOI":"10.3945\/ajcn.2009.27462T","article-title":"Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones","volume":"90","author":"Kokrashvili","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.apsb.2021.04.001_bib233","doi-asserted-by":"crossref","first-page":"118508","DOI":"10.1016\/j.ijpharm.2019.118508","article-title":"Oral delivery of imatinib through galactosylated polymeric nanoparticles to explore the contribution of a saccharide ligand to absorption","volume":"568","author":"Li","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib234","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejpb.2009.04.009","article-title":"Targeting nanoparticles to m cells with non-peptidic ligands for oral vaccination","volume":"73","author":"Fievez","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1021\/acsmacrolett.7b00035","article-title":"Noncompetitive active transport exploiting intestinal transferrin receptors for oral delivery of proteins by tunable nanoplatform","volume":"6","author":"Ganugula","year":"2017","journal-title":"ACS Macro Lett"},{"key":"10.1016\/j.apsb.2021.04.001_bib236","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/pharmaceutics11070298","article-title":"Delivery of nanoparticles across the intestinal epithelium via the transferrin transport pathway","volume":"11","author":"Yong","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.04.001_bib237","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1021\/acs.molpharmaceut.5b00222","article-title":"Enhancing glioblastoma-specific penetration by functionalization of nanoparticles with an iron-mimic peptide targeting transferrin\/transferrin receptor complex","volume":"12","author":"Kang","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib238","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1039\/C7TB02450A","article-title":"Iron-mimic peptide converts transferrin from foe to friend for orally targeting insulin delivery","volume":"6","author":"Liu","year":"2018","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2021.04.001_bib239","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2020.08.005","article-title":"Engineered albumin-functionalized nanoparticles for improved fcrn binding enhance oral delivery of insulin","volume":"327","author":"Azevedo","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib240","doi-asserted-by":"crossref","first-page":"44354","DOI":"10.1021\/acsami.8b20821","article-title":"Microfluidic nanoassembly of bioengineered chitosan-modified FcRn-targeted porous silicon nanoparticles @ hypromellose acetate succinate for oral delivery of anti-diabetic peptides","volume":"10","author":"Martins","year":"2018","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2021.04.001_bib241","first-page":"290","article-title":"Human organic solute transporter (host): protein interaction and membrane sorting process","volume":"3","author":"Sun","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"10.1016\/j.apsb.2021.04.001_bib242","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1021\/mp200291x","article-title":"Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach","volume":"8","author":"Varghese Gupta","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib243","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biomaterials.2017.10.022","article-title":"Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery","volume":"151","author":"Fan","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib244","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jconrel.2017.07.045","article-title":"Bioinspired butyrate-functionalized nanovehicles for targeted oral delivery of biomacromolecular drugs","volume":"262","author":"Wu","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.addr.2011.07.003","article-title":"Gut-associated lymphoid tissues for the development of oral vaccines","volume":"64","author":"Kunisawa","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib246","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1359-6446(05)03536-1","article-title":"Intestinal peyer's patch m cells and oral vaccine targeting","volume":"10","author":"Brayden","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib247","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0264-410X(01)00258-4","article-title":"Targeting polymerised liposome vaccine carriers to intestinal M cells","volume":"20","author":"Clark","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2021.04.001_bib248","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jconrel.2004.10.032","article-title":"Bioadhesive interaction and hypoglycemic effect of insulin-loaded lectin-microparticle conjugates in oral insulin delivery system","volume":"102","author":"Kim","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib249","doi-asserted-by":"crossref","first-page":"7738","DOI":"10.1016\/j.biomaterials.2010.06.059","article-title":"Targeted delivery of chitosan nanoparticles to peyer's patch using M cell-homing peptide selected by phage display technique","volume":"31","author":"Yoo","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2021.04.001_bib250","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.ijpharm.2015.10.078","article-title":"Goblet cell targeting nanoparticle containing drug-loaded micelle cores for oral delivery of insulin","volume":"496","author":"Zhang","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib251","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1073\/pnas.0900029106","article-title":"Dendritic cell targeting of bacillus anthracis protective antigen expressed by lactobacillus acidophilus protects mice from lethal challenge","volume":"106","author":"Mohamadzadeh","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.04.001_bib252","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055143","article-title":"Colonic immune stimulation by targeted oral vaccine","volume":"8","author":"Kathania","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.04.001_bib253","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2014.04.051","article-title":"Nano-chemotherapeutics: maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers","volume":"193","author":"Ryan","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib254","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1015880819328","article-title":"Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration","volume":"7","author":"Supersaxo","year":"1990","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0005-2736(97)00122-3","article-title":"Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: II. influence of liposomal size, lipid composition and lipid dose","volume":"1328","author":"Oussoren","year":"1997","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"10.1016\/j.apsb.2021.04.001_bib256","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2021.04.001_bib257","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addr.2019.09.005","article-title":"Physical and chemical profiles of nanoparticles for lymphatic targeting","volume":"151","author":"Ke","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib258","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17425247.2018.1503249","article-title":"Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs","volume":"15","author":"Managuli","year":"2018","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib259","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nrd4608","article-title":"From sewer to saviour\u2014targeting the lymphatic system to promote drug exposure and activity","volume":"14","author":"Trevaskis","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2021.04.001_bib260","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/01932691.2010.488497","article-title":"Insulin-loaded SLN prepared with the emulsion dilution technique: in\u00a0vivo tracking of nanoparticles after oral administration to rats","volume":"32","author":"Trotta","year":"2011","journal-title":"J Dispersion Sci Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib261","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.addr.2012.07.012","article-title":"Fatty acids as therapeutic auxiliaries for oral and parenteral formulations","volume":"65","author":"Hackett","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib262","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2005.05.019","article-title":"Nanoparticle uptake by the oral route: fulfilling its potential?","volume":"2","author":"Florence","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib263","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1039\/C6TB00237D","article-title":"Glucan microparticles thickened with thermosensitive gels as potential carriers for oral delivery of insulin","volume":"4","author":"Xie","year":"2016","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2021.04.001_bib264","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1039\/C5TB02706C","article-title":"Tracking translocation of glucan microparticles targeting m cells: implications for oral drug delivery","volume":"4","author":"Xie","year":"2016","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2021.04.001_bib265","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1023\/A:1016085108889","article-title":"Gastrointestinal uptake of biodegradable microparticles: effect of particle size","volume":"13","author":"Desai","year":"1996","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib266","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.2042-7158.1990.tb07033.x","article-title":"Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency","volume":"42","author":"Jani","year":"1990","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib267","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/S0264-410X(94)80038-2","article-title":"Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA\/II encapsulated in biodegradable microspheres","volume":"12","author":"Tacket","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2021.04.001_bib268","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0264-410X(02)00613-8","article-title":"Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen","volume":"21","author":"Katz","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2021.04.001_bib269","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1021\/acs.chemrev.7b00246","article-title":"Introduction: ionic liquids","volume":"117","author":"Lei","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib270","doi-asserted-by":"crossref","first-page":"119842","DOI":"10.1016\/j.ijpharm.2020.119842","article-title":"Ionic liquids containing ketoconazole improving topical treatment of T. Interdigitale infection by synergistic action","volume":"589","author":"Wu","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib271","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ijpharm.2019.01.021","article-title":"Improving dermal delivery of hydrophilic macromolecules by biocompatible ionic liquid based on choline and malic acid","volume":"558","author":"Wu","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib272","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijbiomac.2020.02.072","article-title":"Improving dermal delivery of hyaluronic acid by ionic liquids for attenuating skin dehydration","volume":"150","author":"Wu","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2021.04.001_bib273","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1021\/acs.chemrev.6b00562","article-title":"Biological activity of ionic liquids and their application in pharmaceutics and medicine","volume":"117","author":"Egorova","year":"2017","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib274","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.1073\/pnas.1403995111","article-title":"Ionic liquids as a class of materials for transdermal delivery and pathogen neutralization","volume":"111","author":"Zakrewsky","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.04.001_bib275","doi-asserted-by":"crossref","first-page":"1601411","DOI":"10.1002\/adhm.201601411","article-title":"Transdermal protein delivery using choline and geranate (CAGE) deep eutectic solvent","volume":"6","author":"Banerjee","year":"2017","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib276","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1073\/pnas.1722338115","article-title":"Ionic liquids for oral insulin delivery","volume":"115","author":"Banerjee","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2021.04.001_bib277","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jconrel.2020.03.018","article-title":"Oral delivery of sorafenib through spontaneous formation of ionic liquid nanocomplexes","volume":"322","author":"Shi","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib278","first-page":"2002912","article-title":"Ionic liquids and deep eutectic solvents for enhanced delivery of antibodies in the gastrointestinal tract","volume":"n\/a","author":"Angsantikul","year":"2020","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib279","doi-asserted-by":"crossref","first-page":"118584","DOI":"10.1016\/j.ijpharm.2019.118584","article-title":"Improving the hypoglycemic effect of insulin via the nasal administration of deep eutectic solvents","volume":"569","author":"Li","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib280","article-title":"Mucoadhesive ionic liquid gel patches for oral delivery","author":"Peng","year":"2020","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.apsb.2021.04.001_bib281","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1021\/acsbiomaterials.9b00243","article-title":"The influence of water on choline-based ionic liquids","volume":"5","author":"Tanner","year":"2019","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.apsb.2021.04.001_bib282","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jconrel.2017.11.048","article-title":"Microneedles as the technique of drug delivery enhancement in diverse organs and tissues","volume":"270","author":"Rzhevskiy","year":"2018","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib283","first-page":"41","article-title":"Non-transdermal microneedles for advanced drug delivery","volume":"165\u2013166","author":"Lee","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib284","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/17425247.2018.1471059","article-title":"Drug delivery using microneedle patches: not just for skin","volume":"15","author":"Lee","year":"2018","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib285","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/jps.24182","article-title":"Microneedles for drug delivery via the gastrointestinal tract","volume":"104","author":"Traverso","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib286","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41591-019-0598-9","article-title":"A luminal unfolding microneedle injector for oral delivery of macromolecules","volume":"25","author":"Abramson","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2021.04.001_bib287","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41591-019-0606-0","article-title":"Microneedle patch drug delivery in the gut","volume":"25","author":"Prausnitz","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2021.04.001_bib288","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1126\/science.aau2277","article-title":"An ingestible self-orienting system for oral delivery of macromolecules","volume":"363","author":"Abramson","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.apsb.2021.04.001_bib289","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf6413","article-title":"An oral microjet vaccination system elicits antibody production in rabbits","volume":"9","author":"Aran","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2021.04.001_bib290","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1021\/acsami.5b03555","article-title":"N-Trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption","volume":"7","author":"Sheng","year":"2015","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.apsb.2021.04.001_bib291","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2006.09.015","article-title":"Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin","volume":"116","author":"Yin","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib292","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jconrel.2007.04.021","article-title":"Pegylated PLGA-based nanoparticles targeting M cells for oral vaccination","volume":"120","author":"Garinot","year":"2007","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib293","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejphar.2017.10.051","article-title":"PLGA nanoparticles loaded with beta-lactoglobulin-derived peptides modulate mucosal immunity and may facilitate cow's milk allergy prevention","volume":"818","author":"Kostadinova","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib294","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1021\/mp400184v","article-title":"In\u00a0vitro and in\u00a0vivo evaluation of osteoporosis therapeutic peptide PTH 1\u201334 loaded pegylated chitosan nanoparticles","volume":"10","author":"Narayanan","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib295","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.2217\/nnm-2016-0291","article-title":"Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery","volume":"11","author":"Marasini","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib296","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jconrel.2019.10.049","article-title":"Stimuli-responsive self-assembled dendrimers for oral protein delivery","volume":"315","author":"Zeng","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib297","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejpb.2010.12.008","article-title":"In\u00a0vitro and in\u00a0vivo evaluation of WGA\u2013carbopol modified liposomes as carriers for oral peptide delivery","volume":"77","author":"Makhlof","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib298","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/jps.24215","article-title":"Improved oral bioavailability of human growth hormone by a combination of liposomes containing bio-enhancers and tetraether lipids and omeprazole","volume":"103","author":"Parmentier","year":"2014","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib299","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1016\/j.vaccine.2011.05.015","article-title":"Archaeosomes with encapsulated antigens for oral vaccine delivery","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.apsb.2021.04.001_bib300","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejpb.2014.04.007","article-title":"Mannose derivative and lipid a dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system","volume":"88","author":"Wang","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib301","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.colsurfb.2010.08.027","article-title":"Investigation of lectinized liposomes as M-cell targeted carrier-adjuvant for mucosal immunization","volume":"82","author":"Gupta","year":"2011","journal-title":"Colloids Surf, B"},{"key":"10.1016\/j.apsb.2021.04.001_bib302","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jddst.2016.10.012","article-title":"Development and evaluation of insulin-loaded cationic solid lipid nanoparticles for oral delivery","volume":"36","author":"Hecq","year":"2016","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib303","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ejpb.2014.06.011","article-title":"Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs","volume":"88","author":"Fan","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib304","first-page":"23","article-title":"Nanoemulsions coated with alginate\/chitosan as oral insulin delivery systems: preparation, characterization, and hypoglycemic effect in rats","volume":"8","author":"Li","year":"2013","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2021.04.001_bib305","doi-asserted-by":"crossref","first-page":"1809015","DOI":"10.1002\/adfm.201809015","article-title":"Phase-changeable nanoemulsions for oral delivery of a therapeutic peptide: toward targeting the pancreas for antidiabetic treatments using lymphatic transport","volume":"29","author":"Lin","year":"2019","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib306","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/pharmaceutics11080418","article-title":"Rationally designed dendritic silica nanoparticles for oral delivery of exenatide","volume":"11","author":"Abeer","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.apsb.2021.04.001_bib307","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1039\/C9BM00274J","article-title":"Cell-penetrating peptide together with PEG-modified mesostructured silica nanoparticles promotes mucous permeation and oral delivery of therapeutic proteins and peptides","volume":"7","author":"Tan","year":"2019","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib308","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41551-019-0465-5","article-title":"Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability","volume":"4","author":"Lamson","year":"2020","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2021.04.001_bib309","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.nano.2016.06.003","article-title":"Nanostructured SBA-15 silica: an effective protective vehicle to oral hepatitis B vaccine immunization","volume":"12","author":"Scaramuzzi","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib310","doi-asserted-by":"crossref","first-page":"18185","DOI":"10.1021\/acsomega.0c01792","article-title":"Enhanced oral vaccine efficacy of polysaccharide-coated calcium phosphate nanoparticles","volume":"5","author":"Cao","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.apsb.2021.04.001_bib311","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijbiomac.2013.10.026","article-title":"Chondroitin sulfate-capped gold nanoparticles for the oral delivery of insulin","volume":"63","author":"Cho","year":"2014","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2021.04.001_bib312","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.addr.2016.07.007","article-title":"Oral absorption of peptides and nanoparticles across the human intestine: opportunities, limitations and studies in human tissues","volume":"106","author":"Lundquist","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib313","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/mp200572t","article-title":"Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations","volume":"9","author":"Sonaje","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib314","doi-asserted-by":"crossref","first-page":"115972","DOI":"10.1016\/j.carbpol.2020.115972","article-title":"Construction of an environmentally friendly octenylsuccinic anhydride modified pH-sensitive chitosan nanoparticle drug delivery system to alleviate inflammation and oxidative stress","volume":"236","author":"Yu","year":"2020","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2021.04.001_bib315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1520-6017(200101)90:1<38::AID-JPS5>3.0.CO;2-3","article-title":"Mono-n-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in\u00a0vitro and in\u00a0vivo","volume":"90","author":"Thanou","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib316","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jconrel.2013.10.011","article-title":"Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats","volume":"172","author":"Gradauer","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib317","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1002\/adfm.201001014","article-title":"Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs","volume":"20","author":"Sonaje","year":"2010","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib318","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1007\/s11095-007-9367-4","article-title":"Alginate\/chitosan nanoparticles are effective for oral insulin delivery","volume":"24","author":"Sarmento","year":"2007","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib319","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1007558206506","article-title":"N-Trimethylated chitosan chloride (TMC) improves the intestinal permeation of the peptide drug buserelin in\u00a0vitro (Caco-2 cells) and in\u00a0vivo (rats)","volume":"17","author":"Thanou","year":"2000","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib320","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.msec.2014.10.070","article-title":"Uptake and transport of insulin across intestinal membrane model using trimethyl chitosan coated insulin niosomes","volume":"46","author":"Moghassemi","year":"2015","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.apsb.2021.04.001_bib321","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijbiomac.2018.12.182","article-title":"Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin","volume":"126","author":"Tsai","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2021.04.001_bib322","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.3109\/10717544.2014.1002946","article-title":"Absorption-improving effects of chitosan oligomers based on their mucoadhesive properties: a comparative study on the oral and pulmonary delivery of calcitonin","volume":"23","author":"Zhang","year":"2016","journal-title":"Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib323","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ejps.2012.01.002","article-title":"Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration","volume":"45","author":"Zhang","year":"2012","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib324","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijpharm.2017.07.071","article-title":"Improvement in insulin absorption into gastrointestinal epithelial cells by using molecularly imprinted polymer nanoparticles: microscopic evaluation and ultrastructure","volume":"530","author":"Paul","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib325","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1515\/acph-2017-0020","article-title":"Biomimetic insulin-imprinted polymer nanoparticles as a potential oral drug delivery system","volume":"67","author":"Paul","year":"2017","journal-title":"Acta Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib326","first-page":"595","article-title":"Lipid-based colloidal carriers for peptide and protein delivery\u2013liposomes versus lipid nanoparticles","volume":"2","author":"Martins","year":"2007","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2021.04.001_bib327","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1517\/17425247.2012.717068","article-title":"Oral delivery of peptides and proteins using lipid-based drug delivery systems","volume":"9","author":"Li","year":"2012","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib328","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.drudis.2016.09.024","article-title":"In vivo fate of lipid-based nanoparticles","volume":"22","author":"Qi","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2021.04.001_bib329","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijpharm.2013.05.014","article-title":"Controlled release of cyclosporine a self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs","volume":"452","author":"Zhang","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib330","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jff.2017.01.006","article-title":"Formation and stability of w\/o microemulsion formed by food grade ingredients and its oral delivery of insulin in mice","volume":"30","author":"Li","year":"2017","journal-title":"J Func Food"},{"key":"10.1016\/j.apsb.2021.04.001_bib331","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejpb.2010.07.002","article-title":"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats","volume":"76","author":"Sharma","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib332","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2008.03.018","article-title":"Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme","volume":"129","author":"Cheng","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2021.04.001_bib333","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.apsb.2018.06.005","article-title":"Adapting liposomes for oral drug delivery","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm Sinica B"},{"key":"10.1016\/j.apsb.2021.04.001_bib334","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0014-5793(76)80016-6","article-title":"Oral administration of insulin by encapsulation within liposomes","volume":"62","author":"Patel","year":"1976","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2021.04.001_bib335","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(76)91209-5","article-title":"Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats","volume":"308","author":"Dapergolas","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2021.04.001_bib336","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000179509","article-title":"Orally administered liposome-entrapped insulin in diabetic animals","volume":"16","author":"Arrieta-Molero","year":"1982","journal-title":"Hormone Res Paedia"},{"key":"10.1016\/j.apsb.2021.04.001_bib337","doi-asserted-by":"crossref","first-page":"119682","DOI":"10.1016\/j.ijpharm.2020.119682","article-title":"Insight into the in\u00a0vivo translocation of oral liposomes by fluorescence resonance energy transfer effect","volume":"587","author":"Liu","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib338","first-page":"59","article-title":"Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)","volume":"11","author":"Shukla","year":"2008","journal-title":"J Pharm Pharmaceut Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib339","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/1061186X.2012.747528","article-title":"Characterization and optimization of bilosomes for oral vaccine delivery","volume":"21","author":"Wilkhu","year":"2013","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2021.04.001_bib340","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/138920012800166526","article-title":"Absorption, disposition and pharmacokinetics of solid lipid nanoparticles","volume":"13","author":"Qi","year":"2012","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.apsb.2021.04.001_bib341","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2007.04.007","article-title":"Solid lipid nanoparticles as a drug delivery system for peptides and proteins","volume":"59","author":"Almeida","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib342","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40005-013-0087-y","article-title":"Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery","volume":"43","author":"Yoon","year":"2013","journal-title":"J Pharm Invest"},{"key":"10.1016\/j.apsb.2021.04.001_bib343","first-page":"743","article-title":"Oral insulin delivery by means of solid lipid nanoparticles","volume":"2","author":"Sarmento","year":"2007","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2021.04.001_bib344","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.carbpol.2010.12.042","article-title":"Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system","volume":"84","author":"Sarmento","year":"2011","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.apsb.2021.04.001_bib345","first-page":"3333","article-title":"Solid lipid nanoparticles modified with stearic acid\u2013octaarginine for oral administration of insulin","volume":"7","author":"Zhang","year":"2012","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.apsb.2021.04.001_bib346","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1021\/acs.molpharmaceut.9b00861","article-title":"Effect of surface charges on oral absorption of intact solid lipid nanoparticles","volume":"16","author":"Yu","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib347","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2003.07.015","article-title":"Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin","volume":"277","author":"Mor\u00e7\u00f6l","year":"2004","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib348","doi-asserted-by":"crossref","first-page":"15252","DOI":"10.1039\/C7NR05762H","article-title":"Evaluation of mesoporous silica nanoparticles for oral drug delivery\u2014current status and perspective of msns drug carriers","volume":"9","author":"Florek","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.apsb.2021.04.001_bib349","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ijpharm.2014.07.049","article-title":"Preparation and characterization of peg-coated silica nanoparticles for oral insulin delivery","volume":"473","author":"Andreani","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib350","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1039\/C3TB21494J","article-title":"Polymer-coated spherical mesoporous silica for pH-controlled delivery of insulin","volume":"2","author":"Choi","year":"2014","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.apsb.2021.04.001_bib351","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-42645-5","article-title":"3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2021.04.001_bib352","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.colsurfb.2015.05.014","article-title":"An insight into functionalized calcium based inorganic nanomaterials in biomedicine: trends and transitions","volume":"133","author":"Sharma","year":"2015","journal-title":"Colloids Surf, B"},{"key":"10.1016\/j.apsb.2021.04.001_bib353","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jbm.b.31241","article-title":"Synthesis and characterization of pegylated calcium phosphate nanoparticles for oral insulin delivery","volume":"88","author":"Ramachandran","year":"2009","journal-title":"J Biomed Mater Res B"},{"key":"10.1016\/j.apsb.2021.04.001_bib354","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijbiomac.2020.01.302","article-title":"Modified apple polysaccharide capped gold nanoparticles for oral delivery of insulin","volume":"149","author":"Kumari","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2021.04.001_bib355","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1080\/03639045.2016.1220573","article-title":"Synthesis and characterization of insulin\/zirconium phosphate@ TiO2 hybrid composites for enhanced oral insulin delivery applications","volume":"43","author":"Safari","year":"2017","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.apsb.2021.04.001_bib356","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.nano.2015.05.005","article-title":"Nanoparticles in medicine: current challenges facing inorganic nanoparticle toxicity assessments and standardizations","volume":"11","author":"Hofmann-Amtenbrink","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.apsb.2021.04.001_bib357","doi-asserted-by":"crossref","first-page":"1805730","DOI":"10.1002\/adma.201805730","article-title":"Degradability and clearance of inorganic nanoparticles for biomedical applications","volume":"31","author":"Yang","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2021.04.001_bib358","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4155\/TDE.15.47","article-title":"Why most oral insulin formulations do not reach clinical trials","volume":"6","author":"Lopes","year":"2015","journal-title":"Ther Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib359","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.addr.2007.05.006","article-title":"Oral lipid-based formulations","volume":"59","author":"Hauss","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2021.04.001_bib360","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jps.2600830336","article-title":"Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation","volume":"83","author":"Kovarik","year":"1994","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib361","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/bip.20936","article-title":"DDAVP (desmopressin) and solid phase peptide synthesis","volume":"90","author":"Zaoral","year":"2008","journal-title":"Pept Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib362","series-title":"Minirin\u00ae Tablets\u2014New Zealand data sheet","year":"2010"},{"key":"10.1016\/j.apsb.2021.04.001_bib363","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1107\/S0907444994006104","article-title":"Structure of octreotide, a somatostatin analogue","volume":"51","author":"Pohl","year":"1995","journal-title":"Acta Crystallogr D"},{"key":"10.1016\/j.apsb.2021.04.001_bib364","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1210\/jc.2012-1179","article-title":"Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression","volume":"97","author":"Tuvia","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2021.04.001_bib365","unstructured":"https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT01923181?term=oral+semaglutide&phase=1&draw=2&rank=1."},{"key":"10.1016\/j.apsb.2021.04.001_bib366","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejphar.2010.09.019","article-title":"Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit","volume":"649","author":"Busby","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2021.04.001_bib367","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/00365548.2010.544671","article-title":"Systemic absorption of oral vancomycin in patients with clostridium difficile infection","volume":"43","author":"Rao","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.apsb.2021.04.001_bib368","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s11095-013-1233-y","article-title":"Improving the stability and activity of oral therapeutic enzymes\u2014recent advances and perspectives","volume":"31","author":"Fuhrmann","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.apsb.2021.04.001_bib369","unstructured":"Company Announcement: financial report for the period 1 January 2015 to 30 June 2015. Novo Nordisk. Available from: https:\/\/www.novonordisk.com\/content\/dam\/Denmark\/HQ\/investors\/irmaterial\/quarterly_financial_reports\/2015\/20150806_finanical%20report_Q2%202015_UK.pdf [Accessed August 12, 2019]."},{"key":"10.1016\/j.apsb.2021.04.001_bib370","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2012.11.004","article-title":"Time\u2013action profile of an oral enteric insulin formulation in healthy Chinese volunteers","volume":"34","author":"Li","year":"2012","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.apsb.2021.04.001_bib371","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059524","article-title":"Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study","volume":"8","author":"Eldor","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2021.04.001_bib372","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1177\/1932296814529988","article-title":"Oral insulin reloaded: a structured approach","volume":"8","author":"Zijlstra","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib373","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/cts.12609","article-title":"Impact of insulin tregopil and its permeation enhancer on pharmacokinetics of metformin in healthy volunteers: randomized, open-label, placebo-controlled, crossover study","volume":"12","author":"Khedkar","year":"2019","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.apsb.2021.04.001_bib374","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/cpdd.730","article-title":"Pharmacokinetics and pharmacodynamics of insulin tregopil in relation to premeal dosing time, between meal interval, and meal composition in patients with type 2 diabetes mellitus","volume":"9","author":"Khedkar","year":"2020","journal-title":"Clin Pharmacol Drug Develop"},{"key":"10.1016\/j.apsb.2021.04.001_bib375","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/193229680900300627","article-title":"Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation","volume":"3","author":"Geho","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib376","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/1932296814524871","article-title":"A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus","volume":"8","author":"Geho","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.apsb.2021.04.001_bib377","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.joca.2009.08.004","article-title":"The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study","volume":"18","author":"Karsdal","year":"2010","journal-title":"Osteoarthr Cartilage"},{"key":"10.1016\/j.apsb.2021.04.001_bib378","unstructured":"https:\/\/www.protagonist-inc.com\/pipeline\/product-candidates\/."},{"key":"10.1016\/j.apsb.2021.04.001_bib379","unstructured":"http:\/\/avaxiabiologics.com\/programs\/avx-470.php."},{"key":"10.1016\/j.apsb.2021.04.001_bib380","unstructured":"http:\/\/protalix.com\/pipeline\/."},{"key":"10.1016\/j.apsb.2021.04.001_bib381","unstructured":"Sung HW, Liao ZX, Peng SF, Tu H, inventors; GP Medical, Inc., National Tsing Hua University, assignee. Nanoparticles for protein drug delivery. United States patent US No. 8283317B1. 2012 Oct 9."},{"key":"10.1016\/j.apsb.2021.04.001_bib382","unstructured":"Transgene reports excellent results from TrabiOralTM oral insulin studies, Available from: http:\/\/www.transgenebiotek.com\/images\/inner\/news\/press_release_120521_tbl_trabioral_insulin_efficacy_studies.pdf2012 [Accessed 7 December, 2015]."},{"key":"10.1016\/j.apsb.2021.04.001_bib383","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425247.2016.1206074","article-title":"Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes","volume":"14","author":"Thwala","year":"2017","journal-title":"Expet Opin Drug Deliv"},{"key":"10.1016\/j.apsb.2021.04.001_bib384","unstructured":"https:\/\/emisphere.com\/technology\/."},{"key":"10.1016\/j.apsb.2021.04.001_bib385","first-page":"68","article-title":"Novel formulations for non-invasive delivery & stabilization of peptides","volume":"13","author":"Maggio","year":"2013","journal-title":"Biopolymers"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521001167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383521001167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:57:08Z","timestamp":1761929828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383521001167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":385,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S2211383521001167"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2021.04.001","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral delivery of proteins and peptides: Challenges, status quo and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}